Technology Transfer Office

Transforming Our Discoveries Into Therapeutics

The Technology Transfer Office embodies the spirit of the National Jewish Health brand promise, Science Transforming Life^®. We accelerate the development of basic scientific research toward clinical application by identifying and protecting the institution's intellectual property and facilitating business partnerships for technology development, licensing, and commercialization.

National Jewish Health currently has in its portfolio:

• 179 active technologies developed from our research
• 55 active US patents protecting these technologies
• 50 percent of those active US patents are licensed to biotechnology companies for the development of therapeutics consistent with the spirit of the National Jewish Health brand promise, Science Transforming Life^®.

Additionally, in the 19 years since the Technology Transfer Office was created, National Jewish Health has:

• executed 219 license agreements, of which 132 are still active;
• executed a total of 1865 material transfer agreements; and
• helped create 8 start-up companies.

Technologies from National Jewish Health

To browse a list of the technologies ready for licensing or further development, select one of the following:

• Therapeutics and Diagnostics
• Research Tools: Antibodies, Cell Lines, Animal Models & Transgenic Mice
• Biomedical Devices
• Start-Up Companies created with National Jewish Health technologies

Featured Technology:  Novel TLR Inhibitors Prevent Respiratory Syncytial Virus Infection In Vivo